Spotlight February 2021: Nanoobjects in the COVID-vaccine – scientifically correct?

Home > Spotlight February 2021: Nanoobjects in the COVID-vaccine – scientifically correct?

The COVID-19 pandemic induces very different reactions of people on the internet (https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm) and in the social networks. Without following the conspiracy theories as “5G nanochip hidden in COVID vaccines” some news as “COVID vaccines induce allergic reactions” should be scientifically recognised. The picture from the 5G-nanochip whose plan goes viral on the internet is now exposed as fake and shows a guitar pedal. Quite different the recent news about allergic responses after injection of the COVID vaccine [1-3]. Is it true, and how about nanoparticles in vaccines?

Firstly, we should know that the active ingredient within the new vaccines are very sensitive molecules (the so-called mRNA) which must not only be cooled during transport but also would immediately be degraded after injection if not explicitly be stabilized by a special nano-shell. Here the principles of nanomedicine are adopted as the instable RNA-molecule is packed into a lipid layer containing stabilizing polymers (e.g. polyethylene glycol = PEG and others) [4, 5]. These polymers are part of the transport system which delivers the active agent to the cells in our body which start the anti-viral machinery. Unfortunately, such molecules may have a disadvantage because a small part of the population responds sensitive to polymers such as PEG which has been observed in 12 patients after getting the vaccine [1, 3]. The portion of sensitive people is very small but not negligible (currently more than 32 Mio. people have been vasccinated, as of January 2021), thus, it is important to know about the ingredients [please find the full list of the two recent vaccines in 3] and to discuss these with the treating physician. Scientific fact is: the size of the lipid vesicles (nano) is not of importance in relation to adverse effects. Ingredients such as the polymers of the shell around the active agent may induce problems, but the advantage of a COVID vaccination is indisputable.

If someone wants to know more about nanoparticles and vaccination, please visit the website of the Helmholtz Centre for Infection Research: https://www.helmholtz-hzi.de/en/news-events/stories/vaccination-with-nanoparticles/ .

 

Literature:

  1. de Vrieze, J (2021)  Pfizer’s vaccine raises allergy concerns. Science, 371(6524): 10-11.
  2. Kleine-Tebbe, J et al. (2021) Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences. Allergol Select, 5 26-28.
  3. Worm, M et al. (2021) Covid-19 vaccination and risk of anaphylaxis – Recommendations for practical management. MMW Fortschr Med, 163(1): 48-51.
  4. Editorial (2020) Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol, 15(12): 963
  5. Abd Ellah, NH et al. (2020) Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine (Lond), 15(21): 2085-2102.
Spotlight February 2021: Nanoobjects in the COVID-vaccine – scientifically correct?

Weitere Spotlights


Spotlight July 2022: New definition on nanomaterials published

Spotlight July 2022: New definition on nanomaterials published

The European Union has published a new definition for nanomaterials as of June 2022. It is recommended that this be used as a basis for future legislation. The new documents can be found on the EC website. In the new “nanodefinition”, the essential components such as the origin or the size range of the particles […]

Read more

Spotlight November 2023: Early Awareness and Action System for Advanced Materials (Early4AdMa)

Spotlight November 2023: Early Awareness and Action System for Advanced Materials (Early4AdMa)

Advanced materials hold immense potential to address global challenges such as environmental degradation, transformation of the energy sector, and development towards circularity. To harness their benefits while ensuring safety and sustainability, regulatory bodies, scientific communities, and industries have recognized the need for proactive approaches. The “Early4AdMa” system is a pre-regulatory risk governance tool for advanced […]

Read more

Spotlight October 2020: Nanosafety – Topic of the Future

Spotlight October 2020: Nanosafety – Topic of the Future

Research on nanosafety is a driver of innovation as the spotlight in July has demonstrated. But furthermore, this research field is built on routine as well if researchers look for the “needle in the haystack”. In many areas the safety research initiates the development of new methods, e.g. for the determination of nanoparticles within exposed organisms via […]

Read more

Spotlight August 2021: Towards FAIR nanosafety data

Spotlight August 2021: Towards FAIR nanosafety data

In August we would like to present a paper on FAIR data. The paper published in Nature Nanotechnology in June 2021 summarises the challenges and provides recommendations for the efficient reuse of nanosafety data in line with the recently established FAIR guiding principles: findable, accessible, interoperable and reusable. This article summarises the know-how on the […]

Read more

Skip to content